0
Abstract: Slide Presentations |

EFFECT OF 16 WEEKS OF BOSENTAN-BASED THERAPY ON HEMODYNAMICS AND 6-MINUTE WALK TEST DISTANCE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE COMPASS-3 STUDY FREE TO VIEW

Francisco J. Soto, MD*; Srinivas Murali, MD; Myung H. Park, MD; Fernando Torres, MD; Devendra N. Amin, MD; Himanshu Gupta, MD; Raymond L. Benza, MD
Author and Funding Information

Medical College of Wisconsin, Milwaukee, WI


Chest


Chest. 2009;136(4_MeetingAbstracts):33S. doi:10.1378/chest.136.4_MeetingAbstracts.33S-e
Text Size: A A A
Published online

Abstract

PURPOSE:  COMPASS-3 is a prospective, multi-center study which uses a targeted 6-minute walk test distance (6-MWD) threshold approach to guide bosentan-based combinational therapy and assess the utility of cardiac MRI (cMRI) compared with right heart catheterization (RHC) and echocardiography to evaluate prognosis in pulmonary arterial hypertension (PAH).

METHODS:  One hundred therapy-naεve PAH patients with baseline 6-MWD 150–360m will receive bosentan for 4 months. Those not reaching a 6-MWD >380 m will have have sildenafil added (20 mg tid) while the others will continue on bosentan monotherapy (3 months for each group). Evaluations are performed at baseline, 16 weeks and 28 weeks. At this time, 53 patients have completed a Week 16 follow-up visit and these data are reported.

RESULTS:  The mean±SD age was 56±15 years and 83% were female. We found improvements in NT-pro-BNP, WHO functional class and hemodynamics from baseline (Table). Forty-seven percent of patients experienced ≥10% improvement in 6-MWD from baseline and 40% had ≥50m improvement. Only 15% achieved the pre-specified 380m threshold and continued bosentan monotherapy. Results on all 100 patients will be reported at the meeting.

CONCLUSION:  Bosentan monotherapy enabled improvements in hemodynamics, functional class and 6-MWD at 16 weeks.

CLINICAL IMPLICATIONS:  Despite the improvement seen with bosentan monotherapy, it appears that a combination approach (bosentan plus sildenafil) will be needed for the majority of PAH patients in order to potentially achieve the >380m threshold. Analysis of the entire study group (100 patients) will be available at the time of the meeting and should reveal if this combination was successful in reaching the 380m goal.

DISCLOSURE:  Francisco Soto, Grant monies (from industry related sources) Fernando Torres: Research grant-Pfizer. Srinivas Murali: Research support-Actelion, Gilead.; Consultant fee, speaker bureau, advisory committee, etc. Francisco Soto: Advisory board/consultant-Actelion. Fernando Torres: Speaker, Scientific Advisory Board-Actelion; Speaker-Pfizer. Devendra Amin: Speaker-Actelion, Glasko Smith Kline, Bio-Merieux. Himanshu Gupta: consultant-Actelion. Myung Park: Advisory board/consultant-Actelion, Gilead, United Therapeutics. Srinivas Murali: consultant and speaker's bureau-Actelion, Gilead. Raymond Benza: Honoraria-Actelion, Encysive, Pfizer.; No Product/Research Disclosure Information

Tuesday, November 3, 2009

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543